AB1822-HPR EXPERIENCE AND PRELIMINARY DATA IN IMPLEMENTATION OF PRO (PATIENT REPORTED OUTCOME) IN THE DAILY ROUTINE IN INFLAMMATORY ARTHRITIS PATIENTS BASED IN ICHOM-ARTHRITIS MODEL AND A NEW ELECTRONIC PLATFORM (QÜESTCLINIC)
Authors: R. Morlà, N. Sapena, A. Azuaga, Y. Romero, R. Sanmartí, J. A. Gómez-Puerta
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In clinical practice of patients with chronic rheumatic inflammatory disease: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) it is not used to assess quality of life issues in relation to the disease. Patient Reported Outcomes (PROs) can inform about these symptoms suffered by patients using questionnaires or patient reported outcome measures (PROMs). International Consortium Health Outcomes Measures has the main purpose to recognize the crucial role of patients in outcome measures in value-based health, providing a specific ICHOM-arthritis model [1]. <h3>Objectives</h3> To describe the pilot study and some very initial data of the implementation of PROs in an Arthritis Unit of a tertiary hospital based on ICHOM-arthritis through an electronic platform. <h3>Methods</h3> Rheumatologists, nurses, and quality management staff have worked for a period of 2 years in two aspects based on the ICHOM-arthritis model: 1. the use of the "standard set" described that includes the main clinical, and demographic data and a list of generic and specific questionnaires or PROMs to collect for RA, PsA, and axSpA patients. 2. the typology and frequency of visits to establish. MyClinic is an electronic bidirectional platform provided for the Hospital to connect patients and doctors. We designed the Qüestclinic, a space where place questionnaires to send to patients and where patients could answer them. Patients with the 3 diagnoses of adult inflammatory arthritis (RA, PsA, and axSpA) are invited to participate in their visit to outpatient clinics, accepting and signing their informed consent. <h3>Results</h3> We selected 4 generic questionnaires sent to patients to answer in the QuestClinic: MDHAQ (VAS_pain, PGA, VAS_fatigue), EuroQoL, HADS anxiety and depression, and FACIT(FS), and also a disease-specific one: RAID for RA, PsAID for PsA, and BASDAI and BASFI for axAspA. The 12-month visits set at baseline (Vb), 6 months (V6), and 12 months (V12) were performed in a double integrated format (Figure 1). In Vb, 3 tasks are performed: 1. Check questionnaire completion. 2. Initial characteristics (only in Vb): Demographic data (level of studies) and pathological history: smoking, hypertension, heart disease, stroke, COPD, diabetes mellitus, neoplasms, depression, bone fracture, gastric ulcer, other gastric problems, obesity. 3. Monitoring: vital signs and calculation of BMI; adherence to oral or parenteral treatment. Then, in the standard visit the rheumatologist reviews the PROM scores met by the patients in the QüestClinic. Preliminary data in V6 were: A total of 74 records belonging to 55 patients, 40 (54%) female, 39 (53%) RA, 20 (27%) axSpA, and 15 (20%) PsA were collected from February to December 2022. 54 (73%) patients have only visited in baseline and 20 (27.03%) had already 2 visits (V6). The first "snapshot" of the median of generic PROMs (VAS-pain, PGA, VAS-fatigue, HADS-anxiety, and depression) for the diseases were around a median of 4 for pain, PGA, fatigue, and depression, but higher for anxiety in an unselected group of inflammatory chronic rheumatic disease patients (Table 1). <h3>Conclusion</h3> We describe the functional model proposed to implement PROMs in clinical routine to cover the most important PRO dimensions of quality of life of disease and we present here the first picture of preliminary data. <h3>Reference</h3> [1] Oude Voshaar MAH, <i>et al</i>.. Arthritis Care Res (Hoboken). 2019;71:1556-65. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Rosa Morlà: None declared, Nuria Sapena: None declared, Ana Azuaga: None declared, Yolanda Romero: None declared, Raimón Sanmartí Speakers bureau: Abbvie, BMS, Lilly, Pfizer, Roche, Consultant of: Abbvie, BMS, Lilly, Pfizer, Roche, José A Gómez-Puerta Speakers bureau: Abbvie, Astra Zeneca, BMS, GSK, Galápagos, Lilly, Pfizer, Roche and Sanofi, Consultant of: Abbvie, Astra Zeneca, BMS, GSK, Galápagos, Lilly, Pfizer, Roche and Sanofi.